We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+8.81%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.12B
AUM Growth
+$515M
Cap. Flow
+$653M
Cap. Flow %
10.66%
Top 10 Hldgs %
53.58%
Holding
69
New
14
Increased
25
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$169M
2
NUVL
Nuvalent
NUVL
+$140M
3
OCUL icon
Ocular Therapeutix
OCUL
+$111M
4
GMAB icon
Genmab
GMAB
+$110M
5
VERA icon
Vera Therapeutics
VERA
+$55.4M

Top Sells

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$242M
2
CYTK icon
Cytokinetics
CYTK
+$125M
3
APLS
Apellis Pharmaceuticals
APLS
+$69.3M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$67.1M
5
MAZE
Maze Therapeutics
MAZE
+$33.9M

Sector Composition

Rank Sector Weight
1 Healthcare 79.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMPS
26
Compass Pathways
CMPS
$1.47B
$67.3M 1.1%
12,161,496
+4,827,173
+66% +$32.5M
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$11.9B
$65M 1.06%
1,150,000
-1,150,000
-50% -$67.1M
BBIO icon
28
BridgeBio Pharma
BBIO
$16.4B
$62.5M 1.02%
841,445
+31,303
+4% +$2.27M
IMCR icon
29
Immunocore
IMCR
$1.7B
$58.2M 0.95%
1,931,884
-72,094
-4% -$2.33M
TNGX icon
30
Tango Therapeutics
TNGX
$4.21B
$57.5M 0.94%
2,750,000
+295,438
+12% +$4.11M
DFTX
31
Definium Therapeutics
DFTX
$5.6B
$56.7M 0.93%
3,000,000
+1,323,460
+79% +$22.5M
TERN
32
DELISTED
Terns Pharmaceuticals
TERN
$56.6M 0.92%
1,073,877
+304,829
+40% +$12.5M
GERN icon
33
Geron
GERN
$911M
$47.3M 0.77%
31,720,278
-790,993
-2% -$1.2M
ANIP icon
34
ANI Pharmaceuticals
ANIP
$1.86B
$46.1M 0.75%
600,000
+122,316
+26% +$9.55M
CRMD icon
35
CorMedix
CRMD
$565M
$42.6M 0.7%
6,274,076
+1,000,000
+19% +$7.39M
ATAI icon
36
AtaiBeckley Inc
ATAI
$2.65B
$42.5M 0.69%
12,000,000
+7,322,711
+157% +$27.6M
CLDX icon
37
Celldex Therapeutics
CLDX
$2.95B
$40.7M 0.67%
1,283,979
-616,759
-32% -$16.8M
COGT icon
38
Cogent Biosciences
COGT
$6.77B
$38.5M 0.63%
1,000,000
+546,898
+121% +$20.2M
CRVS icon
39
Corvus Pharmaceuticals
CRVS
$1.1B
$36.5M 0.6%
+2,491,539
New +$39.8M
DYN icon
40
Dyne Therapeutics
DYN
$4.15B
$36.3M 0.59%
2,000,000
-650,000
-25% -$11.2M
SLNO
41
DELISTED
Soleno Therapeutics
SLNO
$36.1M 0.59%
1,078,710
+78,710
+8% +$3.09M
ACRS icon
42
Aclaris Therapeutics
ACRS
$715M
$35M 0.57%
+9,345,000
New +$31.5M
MANE
43
Veradermics Inc
MANE
$4.5B
$31.6M 0.52%
+500,000
New +$25.2M
VSTM icon
44
Verastem
VSTM
$528M
$30.4M 0.5%
5,740,850
– –
ENGN icon
45
enGene Therapeutics
ENGN
$119M
$29.8M 0.49%
4,377,572
– –
VRDN icon
46
Viridian Therapeutics
VRDN
$2.2B
$27.3M 0.45%
1,393,944
-1,130,889
-45% -$33.6M
XFOR icon
47
X4 Pharmaceuticals
XFOR
$377M
$26.2M 0.43%
6,339,535
+1,325,874
+26% +$4.97M
SLDB icon
48
Solid Biosciences
SLDB
$791M
$25.7M 0.42%
+3,565,062
New +$22.9M
ENTA icon
49
Enanta Pharmaceuticals
ENTA
$362M
$24.7M 0.4%
1,956,867
– –
APGE icon
50
Apogee Therapeutics
APGE
$10.1B
$24M 0.39%
+285,000
New +$20.7M
1
2
3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Deep Track Capital held 69 positions worth $6.12B, up 9.2% from $5.61B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deep Track Capital deployed $653M of net new capital in Q1 2026, opening 14 new positions and adding to 25 existing holdings. Its largest new stake was Alumis Inc: 6,772,595 shares worth $149M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $125M trimmed.

  • Deep Track Capital's largest Q1 2026 buy was Alumis Inc: 6,772,595 shares worth $149M.
  • Deep Track Capital added most to Ocular Therapeutix in Q1 2026, an estimated $111M increase.
  • Deep Track Capital's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $125M.
  • Deep Track Capital fully exited Dynavax Technologies in Q1 2026, selling an estimated $242M.
  • Deep Track Capital's ten largest holdings make up 54% of its $6.12B portfolio in Q1 2026.
  • Deep Track Capital opened 14 new positions and closed 6 in Q1 2026.
  • Deep Track Capital's portfolio value rose 9.2% quarter-over-quarter to $6.12B.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.